**CANCER TREATMENT REGIMENS**

**Clinical Trials:** The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment.

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/ regimens. These regimens are only provided to supplement the latest treatment strategies.

These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

---

**Preoperative Chemoradiation**

Note: All recommendations are category 2A unless otherwise indicated.

### Preferred Regimens

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOISING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paclitaxel + carboplatin</strong> (Category 1)²</td>
<td>Day 1: Paclitaxel 50mg/m² IV + carboplatin AUC 2mg/mL × min IV Repeat weekly for 5 weeks (Days 1, 8, 15, 22, and 29).</td>
</tr>
<tr>
<td><strong>Cisplatin + 5-fluouracil (5-FU)</strong> (Category 1)³⁴</td>
<td>Days 1 and 29: Cisplatin 75–100mg/m² IV Days 1–4 and 29–32: 5-FU 750–1,000mg/m² IV continuous infusion over 24 hours on a 35-day cycle. OR Days 1–5: Cisplatin 15mg/m² IV daily Days 1–5 and Days 22–26: 5-FU 800 mg/m² IV continuous infusion over 24 hours. Cycled every 21 days for 2 cycles.</td>
</tr>
<tr>
<td><strong>Oxaliplatin + 5-FU + leucovorin</strong>⁵</td>
<td>Day 1: Oxaliplatin 85mg/m² and leucovorin 200mg/m² followed by 5-FU 400mg/m² bolus, then 1,600mg/m² 46-hour continuous infusion; the first 3 cycles were delivered during radiotherapy (RT), the other 3 after RT for 6 bimonthly (14 days) cycles.</td>
</tr>
<tr>
<td><strong>Cisplatin + capecitabine</strong> (Category 1)⁶</td>
<td>Day 1: Cisplatin 30mg/m² IV Days 1–5: Capecitabine 800mg/m² orally twice daily Repeat cycle weekly for 5 weeks.</td>
</tr>
<tr>
<td><strong>Oxaliplatin + 5-FU (Category 1)⁷</strong></td>
<td>Days 1, 15, and 29: Oxaliplatin 85mg/m² IV Days 1–33: 5-FU 180mg/m² IV.</td>
</tr>
<tr>
<td><strong>Oxaliplatin + capecitabine</strong> (Category 1)⁶</td>
<td>Days 1, 15, and 29: Oxaliplatin 85mg/m² IV Days 1–5: Capecitabine 625mg/m² orally twice daily for 5 weeks.</td>
</tr>
<tr>
<td><strong>Irinotecan + cisplatin (Category 2B)⁹</strong></td>
<td>Days 1, 8, 22, and 29: Irinotecan 65mg/m² IV plus cisplatin 30mg/m² IV.</td>
</tr>
<tr>
<td><strong>Paclitaxel + 5-FU</strong> (Category 2B)¹⁰</td>
<td>Day 1: Paclitaxel 45mg/m² IV weekly Days 1–5: 5-FU 300mg/m² IV continuous infusion Repeat cycle weekly for 5 weeks.</td>
</tr>
<tr>
<td><strong>Paclitaxel + capecitabine</strong> (Category 2B)¹⁰</td>
<td>Day 1: Paclitaxel 45–50mg/m² IV Days 1–5: Capecitabine 625–825mg/m² orally BID Repeat cycle weekly for 5 weeks.</td>
</tr>
</tbody>
</table>

### Other Regimens

**ECF (epirubicin + cisplatin + 5-FU) (Category 1)¹¹**

**ECF modifications**¹²

**5-FU + cisplatin (Category 1)¹³**

---

**continued**
Definitive Chemoradiation (Nonsurgical)\(^1\)

### Preferred Regimens

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| **Cisplatin + 5-FU (Category 1)\(^{1,4}\)** | **Day 1:** Cisplatin 75–100mg/m\(^2\) IV  
**Days 1–4:** 5-FU 750–1,000mg/m\(^2\)/day continuous IV infusion over 24 hours daily. Repeat cycle every 28 days for 2–4 cycles with radiation followed by 2 cycles without radiation. |
| **Oxaliplatin + 5-FU (Category 1)\(^{7,15}\)** | **Days 1, 15, and 29:** Oxaliplatin 85mg/m\(^2\) IV for 3 doses  
**Days 1–33:** 5-FU 180mg/m\(^2\) IV daily.  
**OR**  
**Day 1:** Oxaliplatin 85mg/m\(^2\) IV  
**Day 1:** Leucovorin 400mg/m\(^2\) IV  
**Day 1:** 5-FU 400mg/m\(^2\) IVP  
**Days 1 and 2:** 5-FU 800mg/m\(^2\) continuous IV over 24 hours daily. Repeat cycle every 14 days for 3 cycles with radiation followed by 3 cycles without radiation. |
| **Cisplatin + capecitabine (Category 1)** | **Day 1:** Cisplatin 30mg/m\(^2\) IV  
**Days 1–5:** Capecitabine 800mg/m\(^2\) orally twice daily. Repeat cycle weekly for 5 weeks. |
| **Oxaliplatin + capecitabine (Category 1)** | **Days 1, 15, and 29:** Oxaliplatin 85mg/m\(^2\) IV  
**Days 1–5:** Capecitabine 625mg/m\(^2\) orally twice daily for 5 weeks. |
| **Paclitaxel + carboplatin** | **Day 1:** Paclitaxel 50mg/m\(^2\) IV and carboplatin AUC 2 mg/mL × min IV once weekly for 5 weeks. |

### Other Regimens

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| **Paclitaxel + cisplatin** | **Days 1, 8, 15, and 22:** Paclitaxel 60mg/m\(^2\) IV  
**Day 1:** Cisplatin 75mg/m\(^2\) IV given for 1 cycle. |
| **Docetaxel + cisplatin** | **Days 1 and 22:** Docetaxel 60mg/m\(^2\) IV  
**Days 1 and 22:** Cisplatin 60–80mg/m\(^2\) IV given for 1 cycle.  
**OR**  
**Day 1:** Docetaxel 20–30mg/m\(^2\) IV  
**Day 1:** Cisplatin 20–30mg/m\(^2\) IV given for weekly for 5 weeks. |
| **Irinotecan + cisplatin (Category 2B)** | **Days 1, 8, 22, and 29:** Irinotecan 65mg/m\(^2\) IV  
**Days 1, 8, 22, and 29:** Cisplatin 30mg/m\(^2\) IV. |
| **Paclitaxel + 5-FU (Category 2B)** | **Day 1:** Paclitaxel 45mg/m\(^2\) IV  
**Days 1–5:** 5-FU 300mg/m\(^2\) IV continuous infusion daily. Repeat cycle weekly for 5 weeks. |
| **Paclitaxel + capecitabine (Category 2B)** | **Day 1:** Paclitaxel 45–50mg/m\(^2\) IV  
**Days 1–5:** Capecitabine 625–825mg/m\(^2\) PO twice daily. Repeat cycle weekly for 5 weeks. |

### Postoperative Chemoradiation (for adenocarcinoma or gastroesophageal junction only)\(^1\)

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| **5-FU + leucovorin** | **Days 1–5:** 5-FU 425mg/m\(^2\)/day IV and leucovorin 20mg/m\(^2\)/day IV, followed by chemoradiotherapy beginning 4 weeks after the start of the initial cycle of chemotherapy.  
**Chemoradiotherapy:** 4,500cGy of radiation at 180cGy/day, 5 days/week for 5 weeks, with 5-FU 400mg/m\(^2\)/day IV and leucovorin 20mg/m\(^2\)/day IV on the first 4 and the last 3 days of radiotherapy.  
At 1 month following completion of radiotherapy, two 5-day cycles of 5-FU 425mg/m\(^2\)/day IV and leucovorin 20mg/m\(^2\)/day IV, given 1 month apart.  
**NOTE:** The NCCN panel acknowledges that the Intergroup 0116 Trial formed the basis for postoperative adjuvant chemoradiation strategy. However, the panel does not recommend the above specified doses or schedule of cytotoxic agents because of concerns regarding toxicity. The panel recommends one of the following modifications instead:  
**Paclitaxel** | **Day 1:** Paclitaxel 45–50mg/m\(^2\) IV  
**Days 1–5:** Capecitabine 625–825mg/m\(^2\) PO twice daily. Repeat cycle weekly for 5 weeks. |

**Continued**
**ESOPHAGEAL AND ESOPHAGOGASTRIC JUNCTION CANCER TREATMENT REGIMENS (Part 3 of 7)**

### Metastatic or Locally Advanced Cancer (where local therapy is not indicated)\(^1\)

#### First-line therapy

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOsing</th>
</tr>
</thead>
</table>
| **Trastuzumab + chemotherapy**  (for HER2-neu malignancies)\(^{34}\) | Day 1: Trastuzumab 8mg/kg IV loading dose (Cycle 1 only); followed by trastuzumab 6mg/kg IV every 3 weeks, plus chemotherapy (Category 2B).  
**OR**  
**Day 1 of Cycle 1:** Trastuzumab 6mg/kg IV loading dose, then 4mg/kg IV every 4 days  
**Day 1:** Cisplatin 80mg/m\(^2\) IV, plus  
**Days 1–14:** Capecitabine 1000mg/m\(^2\) orally twice daily  
**OR Days 1–5:** 5-FU 800mg/m\(^2\) continuous IV infusion (Category 1).  
Repeat cycle every 21 days for 6 cycles. |
| **DCF (docetaxel + cisplatin + 5-FU)** (Category 1)\(^{25}\) | Day 1: Docetaxel 75mg/m\(^2\) IV + cisplatin 75mg/m\(^2\) IV  
**Days 1–5:** 5-FU 1,000mg/m\(^2\) IV continuous infusion over 24 hours.  
Repeat cycle every 28 days. |
| **DCF (docetaxel + leucovorin + cisplatin + 5-FU)**\(^{26}\) | Day 1: Docetaxel 40mg/m\(^2\) IV + leucovorin 400mg/m\(^2\) IV + 5-FU 400mg/m\(^2\) IV, plus  
**Days 1 and 2:** 5-FU 1000mg/m\(^2\) IV continuous infusion over 24 hours (total 2000mg/m\(^2\)), **followed by**  
**Day 3:** Cisplatin 40mg/m\(^2\) IV.  
Repeat cycle every 14 days. |
| **DCF (docetaxel + cisplatin + 5-FU)**\(^{27}\) | Day 1: Docetaxel 60mg/m\(^2\) IV plus cisplatin 60mg/m\(^2\) IV  
**Days 1–4:** 5-FU 750mg/m\(^2\) IV continuous infusion over 24 hours daily.  
Repeat cycle every 21 days. |
| **DCF (docetaxel + cisplatin + 5-FU)**\(^{28}\) | Day 1: Docetaxel 75mg/m\(^2\) IV plus cisplatin 75mg/m\(^2\) IV  
**Days 1–14:** 5-FU 300mg/m\(^2\) IV continuous infusion over 24 hours daily.  
Repeat cycle every 21 days. |
| **Modified DCF (docetaxel + oxaliplatin + leucovorin + cisplatin)**\(^{29}\) | Day 1: Docetaxel 50mg/m\(^2\) IV plus leucovorin 200mg/m\(^2\) IV plus oxaliplatin 85mg/m\(^2\) plus 5-FU 2600mg/m\(^2\) IV continuous infusion over 24 hours.  
Repeat cycle every 14 days. |
| **Modified DCF (docetaxel + oxaliplatin + 5-FU)**\(^{30}\) | Day 1: Docetaxel 50mg/m\(^2\) IV plus oxaliplatin 85mg/m\(^2\)  
**Days 1 and 2:** 5-FU 1200mg/m\(^2\) IV continuous infusion over 24 hours.  
Repeat cycle every 14 days. |
| **Modified DCF (docetaxel + carboplatin + 5-FU)** (Category 2B)\(^{31}\) | Day 1: Docetaxel 75mg/m\(^2\)  
**Day 2:** Carboplatin AUC 6mg/mL × min  
**Days 1–3:** 5-FU 1200mg/m\(^2\) IV continuous infusion over 24 hours daily.  
Repeat cycle every 21 days. |
| **ECF (epirubicin + cisplatin + 5-FU)** (Category 1)\(^{32,33}\) | Day 1: Epirubicin 50mg/m\(^2\) IV bolus + cisplatin 60mg/m\(^2\) IV  
**Days 1–21:** 5-FU 200mg/m\(^2\) IV continuous infusion over 24 hours daily.  
Repeat cycle every 21 days. |
| **ECF modifications (epirubicin + oxaliplatin + 5-FU)** (Category 1)\(^{33}\) | Day 1: Epirubicin 50mg/m\(^2\) IV plus oxaliplatin 130mg/m\(^2\) IV  
**Days 1–21:** 5-FU 200mg/m\(^2\) IV continuous infusion over 24 hours daily.  
Repeat cycle every 21 days. |
| **ECF modifications (epirubicin + cisplatin + capecitabine)** (Category 1)\(^{33}\) | Day 1: Epirubicin 50mg/m\(^2\) IV plus cisplatin 60mg/m\(^2\) IV  
**Days 1–21:** Capecitabine 625mg/m\(^2\) IV orally twice daily.  
Repeat cycle every 21 days. |
| **ECF modifications (epirubicin + oxaliplatin + capecitabine)** (Category 1)\(^{33}\) | Day 1: Epirubicin 50mg/m\(^2\) IV plus oxaliplatin 130mg/m\(^2\) IV  
**Days 1–21:** Capecitabine 625mg/m\(^2\) IV orally twice daily.  
Repeat cycle every 21 days. |
| **Fluoropyrimidine and cisplatin** (5-FU + cisplatin) (Category 1)\(^{34}\) | Day 1: Cisplatin 100mg/m\(^2\) IV  
**Days 1–4:** 5-FU 1,000mg/m\(^2\) IV continuous infusion over 24 hours daily doses of 250mg/m\(^2\) IV over 60 minutes. |
| **Fluoropyrimidine and cisplatin** (5-FU + cisplatin + leucovorin) (Category 1)\(^{34,35}\) | Day 1: Cisplatin 50mg/m\(^2\) IV  
**Day 1:** Leucovorin 200mg/m\(^2\) IV  
**Day 1–5:** 5-FU 2,000mg/m\(^2\) IV continuous infusion over 24 hours.  
Repeat cycle every 14 days. |
| **Fluoropyrimidine and cisplatin** (capecitabine + cisplatin) (Category 1)\(^{34}\) | Day 1: Cisplatin 80mg/m\(^2\) IV  
**Day 1–14:** Capecitabine 1,000mg/m\(^2\) orally twice daily.  
Repeat cycle every 3 weeks. |
| **Fluoropyrimidine and oxaliplatin** (oxaliplatin + leucovorin + 5-FU)\(^{36,37}\) | Day 1: Oxaliplatin 85mg/m\(^2\) IV plus leucovorin 400mg/m\(^2\) IV plus 5-FU 400mg/m\(^2\) IVP  
**Days 1 and 2:** 5-FU 1200mg/m\(^2\) IV continuous infusion over 24 hours daily.  
**OR**  
**Day 1:** Oxaliplatin 85mg/m\(^2\) IV plus leucovorin 200mg/m\(^2\) IV plus 5-FU 400mg/m\(^2\) IVP plus 5-FU 2600mg/m\(^2\) IV continuous infusion over 24 hours daily.  
Repeat cycle every 14 days.  
*continued*
Metastatic or Locally Advanced Cancer (where local therapy is not indicated)1 (continued)

**Preferred Regimens (continued)**

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOsing</th>
</tr>
</thead>
</table>
| Fluoropyrimidine and oxaliplatin (oxaliplatin + capecitabine)38 | Day 1: Oxaliplatin 130mg/m² IV  
Days 1–14: Capecitabine 1000mg/m² orally twice daily.  
Repeat cycle every 21 days. |
| 5-FU and irinotecan (irinotecan + leucovorin + 5-FU) (Category 1)39-41 | Day 1: Irinotecan 80mg/m² IV plus leucovorin 500mg/m² IV plus 5-FU 2000mg/m² IV continuous infusion over 24 hours, weekly for 6 weeks followed by 1 week off treatment  
OR Weekly for 6 weeks followed by 2 weeks off treatment.  
OR Day 1: Irinotecan 180mg/m² IV plus leucovorin 400mg/m² IV plus 5-FU 400mg/m² IVP  
Day 1–2: 5-FU 1200mg/m² IV continuous infusion over 24 hours.  
Repeat cycle every 14 days. |

**Other Regimens**

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOsing</th>
</tr>
</thead>
</table>
| Paclitaxel + cisplatin or carboplatin12-44 | Day 1: Paclitaxel 135–200mg/m² IV  
Day 2: Cisplatin 75mg/m² IV  
Repeat cycle every 21 days.  
OR Day 1: Paclitaxel 90mg/m² IV plus cisplatin 75mg/m² IV  
Repeat cycle every 14 days.  
OR Day 1: Paclitaxel 200mg/m² IV plus carboplatin AUC 5mg/mL × min.  
Repeat cycle every 21 days. |
| Docetaxel + cisplatin28,45,46 | Day 1: Docetaxel 70–85mg/m² IV plus cisplatin 70–75mg/m² IV.  
Repeat cycle every 21 days. |
| Docetaxel + irinotecan (Category 1)47 | Days 1 and 8: Docetaxel 35mg/m² IV plus irinotecan 50mg/m² IV.  
Repeat cycle every 21 days. |
| Fluoropyridimine48,49 | Day 1: Leucovorin 400mg/m² IV plus 5-FU 400mg/m² IVP  
Days 1 and 2: 5-FU 1200mg/m² IV continuous infusion over 24 hours daily.  
Repeat cycle every 14 days.  
OR Days 1–5: 5-FU 800mg/m² IV continuous infusion over 24 hours daily.  
Repeat cycle every 28 days.  
OR Days 1–14: Capecitabine 1000–1250mg/m² orally twice daily.  
Repeat cycle every 21 days. |
| Taxane50-52 | Day 1: Docetaxel 75–100mg/m² IV.  
Repeat cycle every 21 days.  
OR Day 1: Paclitaxel 135–250mg/m² IV.  
Repeat cycle every 21 days.  
OR Days 1, 8, 15, and 22: Paclitaxel 80mg/m² IV once weekly.  
Repeat cycle every 28 days. |

**Second-line Therapy**

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOsing</th>
</tr>
</thead>
</table>
| Trastuzumab + chemotherapy (NOTE: for HER2-neu malignancies)74 | Day 1: Trastuzumab 8mg/kg IV loading dose (Cycle 1 only); followed by trastuzumab 6mg/kg IV every 3 weeks, plus chemotherapy (Category 2B).  
OR Day 1 of Cycle 1: Trastuzumab 6mg/kg IV loading dose, then 4mg/kg IV every 4 days.  
Chemotherapy:  
Day 1: Cisplatin 80mg/m² IV, plus  
Days 1–14: Capecitabine 1000mg/m² orally twice daily OR Days 1–5: 5-FU 800mg/m² continuous IV infusion.  
Repeat cycle every 21 days for 6 cycles. |

**Preferred Regimens**

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOsing</th>
</tr>
</thead>
</table>
| Ramucirumab + paclitaxel (for adenocarcinoma) (Category 1 for EGI adenocarcinoma; Category 2A for esophageal adenocarcinoma)53 | Days 1 and 15: Ramucirumab 8mg/kg IV  
Days 1, 8, and 15: Paclitaxel 80mg/m² IV.  
Repeat cycle every 28 days. |
| Ramucirumab (for adenocarcinoma) (Category 1 for EGI adenocarcinoma; Category 2A for esophageal adenocarcinoma)54 | Days 1 and 15: Ramucirumab 8mg/kg IV.  
Repeat cycle every 28 days. |
## Second-line Therapy

### Preferred Regimens (continued)

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Docetaxel (Category 1)   | Day 1: Docetaxel 75–100mg/m² IV  
Repeat cycle every 21 days.                                                                 |
| Paclitaxel (Category 1)  |  
Day 1: Paclitaxel 135–250mg/m² IV  
Repeat cycle every 21 days.  
OR  
Day 1: Paclitaxel 80mg/m² IV once weekly  
Repeat cycle every 28 days.  
OR  
Days 1, 8, and 15: Paclitaxel 80 mg/m² IV.  
Repeat cycle every 28 days.                                                                 |
| Irinotecan (Category 1)  | Day 1: Irinotecan 250–350mg/m² IV  
Repeat cycle every 21 days.  
OR  
Day 1: Irinotecan 150–180mg/m² IV  
Repeat cycle every 14 days.  
OR  
Days 1 and 8: Irinotecan 125mg/m² IV.  
Repeat cycle every 21 days.                                                                 |
| Docetaxel + irinotecan (Category 2B) | Days 1 and 8: Docetaxel 35mg/m² IV plus irinotecan 50mg/m² IV.  
Repeat cycle every 21 days.                                                                 |
| Mitomycin + irinotecan (Category 2B) | Days 1 and 9: Mitomycin 6mg/m² IV  
Days 2 and 8: Irinotecan 125mg/m².  
Repeat cycle every 28 days.  
OR  
Days 1 and 15: Irinotecan 150mg/m² IV  
Day 1: Mitomycin 8mg/m² IV.  
Repeat cycle every 28 days.  
OR  
Day 1: Irinotecan 125mg/m² IV plus mitomycin 5mg/m² IV.  
Repeat cycle every 14 days.                                                                 |
| Mitomycin + leucovorin + 5-FU (Category 2B) | Days 1 and 22: Mitomycin 10mg/m² IV  
Day 1: Leucovorin 500mg/m² IV plus 5-FU 2600mg/m²/day IV continuous infusion.  
Weekly for 6 weeks, followed by 2 weeks off treatment.                                                                 |

### Other Regimens

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Irinotecan + cisplatin (Category 2B) | Days 1 and 8: Irinotecan 65mg/m² IV plus cisplatin 25–30mg/m² IV.  
Repeat cycle every 21 days.                                                                 |
| Irinotecan + fluoropyridimine (Category 2B) | Day 1: Irinotecan 250mg/m² IV  
Days 1–14: Capecitabine 1000mg/m² PO BID daily.  
Repeat cycle every 21 days.                                                                 |
| Irinotecan + fluoropyridimine (Category 2B) | Day 1: Irinotecan 180mg/m² IV plus leucovorin 400mg/m² IV plus 5-FU 400mg/m²/day IVP  
Days 1 and 2: 5-FU 600–1200mg/m²/day IV continuous infusion on days 1 and 2.  
Repeat cycle every 14 days.                                                                 |
| Mitomycin + leucovorin + 5-FU (Category 2B) | Days 1 and 22: Mitomycin 10mg/m² IV  
Day 1: Leucovorin 500mg/m² IV plus 5-FU 2600mg/m²/day IV continuous infusion.  
Weekly for 6 weeks, followed by 2 weeks off treatment.                                                                 |

### Alternative Regimens for Consideration

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Mitomycin + irinotecan (Category 2B) | Days 1 and 8: Irinotecan 65mg/m² IV plus cisplatin 25–30mg/m² IV.  
Repeat cycle every 21 days.                                                                 |
| Irinotecan + cisplatin (Category 2B) | Days 1 and 8: Irinotecan 65mg/m² IV plus cisplatin 25–30mg/m² IV.  
Repeat cycle every 21 days.                                                                 |

### General Treatment Notes

Chemotherapy regimens should be chosen in the context of performance status, medical comorbidities, toxicity profile, and HER2-neu expression (for adenocarcinoma only). Two-drug cytotoxic regimens are preferred for patients with advanced disease because of lower toxicity. Three-drug cytotoxic regimens should be reserved for medically fit patients with good PS and access to frequent toxicity evaluation. Doses and schedules for any regimen that is not derived from category 1 evidence is a suggestion, and subject to appropriate modifications depending on the circumstances. Infusional fluorouracil and capecitabine may be used interchangeably (except as indicated). Cisplatin and oxaliplatin may be used interchangeably depending on toxicity profile.

* Modified regimens substituting oxaliplatin and/or capecitabine are also acceptable.
† May be coupled with cetuximab administered as an initial dose of cetuximab 400 mg/m² IV on Day 1 over 120 minutes; followed by weekly doses of 250 mg/m² IV over 60 minutes.

continued


References (continued)


